Worldwide Carrier Screening Industry to 2031 - Massive Scope for Adoption of Carrier Screening in Developing Nations Presents Opportunities -

·4 min read

DUBLIN, January 27, 2022--(BUSINESS WIRE)--The "Carrier Screening Market - A Global and Regional Analysis: Focus on Type, Product, Carrier Screening Type, Technology, Indication, and Region - Analysis and Forecast, 2021-2031" report has been added to's offering.

The global carrier screening market is projected to reach $4,479.0 million by 2031, growing from $1,187.4 million in 2020, at a CAGR of 12.67% during the forecast period 2021-2031.

The carrier screening market is an emerging market with huge growth potential. Recent technological advancements are facilitating the adoption of the technology at a rapid pace. Carrier screening are genetic tests that are used for determining if a person is a potential carrier of genetic disorders such as cystic fibrosis (CF), Down's syndrome, Fragile X syndrome, sickle cell anemia, and spinal muscular atrophy (SMA). Carrier screening tests are extensively used by couples considering becoming pregnant to determine the risks of passing genetic anomalies to the child. This study aims at deciphering the potential of carrier screening and its larger role in bolstering the current era of precision medicine in the field of reproductive health.

The growth of the carrier screening market is expected to be driven by the decrease in the cost of sequencing, rising emphasis on early detection and prevention of complex genetic disorders, and increasing maternal age leading to pregnancy complications.

However, there are significant challenges restraining the market growth, such as the regulatory challenges in the field of carrier screening, and the lack of high complexity testing centers. Carrier screening is a hereditary test that gives information about whether a person carries a gene for certain genetic disorders. It is performed before or during pregnancy times. Carrier screening allows a person to find out the chances of having a child with a genetic disorder. Carrier screening involves testing blood, saliva, or tissue extracted from inside the cheeks. In cases of genetic disorders, a person should have two affected genes to have the disorder.

Key Questions Answered in this Report:

  • How is carrier screening revolutionizing the field of reproductive health?

  • What are the major market drivers, challenges, and opportunities in the global carrier screening market?

  • What are the underlying structures resulting in the emerging trends within the global carrier screening market?

  • How is the COVID-19 pandemic impacting the global carrier screening ecosystem?

  • What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?

  • What are the key regulatory implications in developed and developing regions pertaining to the use of carrier screening?

  • What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?

  • How is each market segment expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment?

  • What are the growth opportunities for the carrier screening companies in the region of their operation?

  • Who are the leading players with significant offerings in the global carrier screening market?

  • Which companies are anticipated to be highly disruptive in the future, and why?

Market Dynamics

Growth Drivers

  • Decreasing Cost of Sequencing

  • Rising Emphasis on Early Detection and Prevention of Complex Genetic Disorders

  • Increasing Maternal Age Leading to Pregnancy Complications

  • Rising Funding and Innovation in the carrier Screening Ecosystem


  • Regulatory Challenges in the Field of Carrier Screening

  • Lack of High Complexity Testing Centers

  • Existing Diagnostic Confidence on Conventional Screening Methods


  • Massive Scope for Adoption of Carrier Screening in Developing Nations

Companies Mentioned

  • BGI Group


  • Eurofins Scientific

  • Fulgent Genetics, Inc.

  • Gene by Gene, Ltd.

  • Illumina, Inc.

  • Invitae Corporation

  • Laboratory Corporation of America Holdings

  • Myriad Genetics, Inc.

  • Natera, Inc.

  • OPKO Health

  • Quest Diagnostics Incorporated

  • Sema4

  • Thermo Fisher Scientific Inc.

  • Yourgene Health Plc

For more information about this report visit

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900